1. Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev
- Author
-
Jose H Arteaga, Jorma Hinkula, Edvard C.I Smith, Britta Wahren, Abdalla J. Mohamed, Maria E. Cardona, Kristin Gustafsson, and Birger Christensson
- Subjects
Hiv 1 rev ,Receptors, CCR5 ,business.industry ,viruses ,Human immunodeficiency virus (HIV) ,Down-Regulation ,virus diseases ,Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) ,HIV Infections ,General Medicine ,medicine.disease_cause ,Virology ,RNA interference ,HIV-1 ,Rev gene ,CCR5 receptor ,Small hairpin RNA ,Downregulation and upregulation ,medicine ,Genetics ,Humans ,RNA, Small Interfering ,business ,Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) ,Molecular Biology - Abstract
Treatment with RNAi against HIV-1 transcripts efficiently inhibits viral replication but induces selection of escape mutants; therefore, the CCR5 coreceptor was suggested as an additional target. Blocking viral and host transcripts improved the antiviral effect. We have used short hairpin RNA (shRNA) targeting the human CCR5 (shCCR5) or the HIV-1 rev (shRev) transcripts to demonstrate distinctive properties of anti-CCR5 shRNA: shCCR5 induced more sustained protection than shRev; partial reduction in CCR5 expression substantially decreased HIV-1 infection, and shCCR5 performed better than shRev in the mixed shRNA-treated and untreated cultures. These observations indicate that CCR5 inhibitors should be conveniently included in HIV-1 gene silencing treatment schedules when only a certain cell fraction is protected to further reduce endogenous virus in a properly ART-treated HIV-1 infected individual.
- Published
- 2022